nach oben

Current Hepatology Reports

Erschienen in:

28.04.2017 | Hepatic Cancer (A Singal and A Mufti, Section Editors)

Should AFP (or Any Biomarkers) Be Used for HCC Surveillance?

verfasst von: Hager F. Ahmed Mohammed, Lewis R. Roberts

Erschienen in: Current Hepatology Reports | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The aim of this review is to address the controversy around the use of biomarkers for hepatocellular carcinoma (HCC) surveillance in individuals with cirrhosis or chronic hepatitis B who are at risk for development of liver cancer.

Recent Findings

Recent studies suggest that surveillance for hepatocellular carcinoma is beneficial, even after adjustment for lead time and other biases. Alpha fetoprotein (AFP) is complementary to ultrasound (US) in surveillance, particularly in obese patients and patients with infiltrative tumors. US and AFP are both associated with harms to patients from false-positive overdiagnosis, with US appearing to cause greater harms. Including patient demographic characteristics and additional biomarkers into diagnostic models is beneficial. Recent studies emphasize the advantage of time trends in biomarkers over single cross-sectional measurements.

Summary

AFP and other biomarkers are complementary to US in surveillance for HCC, especially when applied in models including patient variables and incorporating time trends in biomarker levels. With advances in genetic and molecular analysis of tumors, we may be poised at the cusp of a revolution in HCC surveillance.

Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130(7):417–22. doi:10.1007/s00432-004-0552-0.CrossRefPubMed

McMahon BJ, Bulkow L, Harpster A, Snowball M, Lanier A, Sacco F, et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 2000;32(4 Pt 1):842–6. doi:10.1053/jhep.2000.17914.CrossRefPubMed

Kansagara D, Papak J, Pasha AS, O’Neil M, Freeman M, Relevo R, et al. Screening for hepatocellular carcinoma in chronic liver disease: a systematic review. Ann Intern Med. 2014;161(4):261–9. doi:10.7326/M14-0558.CrossRefPubMed

Sherman M. Alphafetoprotein: an obituary. J Hepatol. 2001;34(4):603–5.CrossRefPubMed

Chalasani N, Said A, Ness R, Hoen H, Lumeng L. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol. 1999;94(8):2224–9. doi:10.1111/j.1572-0241.1999.01297.x.CrossRefPubMed

Van Kleek EJ, Schwartz JM, Rayhill SC, Rosen HR, Cotler SJ. Liver transplantation for hepatocellular carcinoma: a survey of practices. J Clin Gastroenterol. 2006;40(7):643–7.CrossRefPubMed

El-Serag HB, Alsarraj A, Richardson P, Davila JA, Kramer JR, Durfee J, et al. Hepatocellular carcinoma screening practices in the Department of Veterans Affairs: findings from a national facility survey. Dig Dis Sci. 2013;58(11):3117–26. doi:10.1007/s10620-013-2794-7.CrossRefPubMed

van Meer S, de Man RA, Coenraad MJ, Sprengers D, van Nieuwkerk KM, Klumpen HJ, et al. Surveillance for hepatocellular carcinoma is associated with increased survival: results from a large cohort in the Netherlands. J Hepatol. 2015;63(5):1156–63. doi:10.1016/j.jhep.2015.06.012.CrossRefPubMed

Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–66. doi:10.1111/liv.12818.CrossRefPubMedPubMedCentral

10.

Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M, et al. Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res. 2016;46(5):372–90. doi:10.1111/hepr.12697.CrossRefPubMed

11.

Singal AG, Yopp A, Skinner CS, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med. 2012;27(7):861–7. doi:10.1007/s11606-011-1952-x.

12.

Ahmed Mohammed HA, Yang JD, Giama NH, Choi J, Ali HM, Mara KC, et al. Factors influencing surveillance for hepatocellular carcinoma in patients with liver cirrhosis. Liver Cancer. 2017;6(2):126–36. doi:10.1159/000450833.CrossRefPubMed

13.

Gopal P, Yopp AC, Waljee AK, Chiang J, Nehra M, Kandunoori P, et al. Factors that affect accuracy of alpha-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2014;12(5):870–7. doi:10.1016/j.cgh.2013.09.053.CrossRefPubMed

14.

Yang JD, Dai J, Singal AG, Gopal P, Addissie B, Nguyen MH, et al. Improved performance of serum alpha-fetoprotein for hepatocellular carcinoma diagnosis in HCV cirrhosis with normal alanine transaminase. Cancer Epidemiol Biomark Prev. 2017; doi:10.1158/1055-9965.EPI-16-0747.

15.

Chung JW, Kim BH, Lee CS, Kim GH, Sohn HR, Min BY, et al. Optimizing surveillance performance of alpha-fetoprotein by selection of proper target population in chronic hepatitis B. PLoS One. 2016;11(12):e0168189. doi:10.1371/journal.pone.0168189.CrossRefPubMedPubMedCentral

16.

Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomark Prev. 2012;21(5):793–9. doi:10.1158/1055-9965.EPI-11-1005.CrossRef

17.

Del Poggio P, Olmi S, Ciccarese F, Di Marco M, Rapaccini GL, Benvegnu L, et al. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2014;12(11):1927–1933 e2. doi:10.1016/j.cgh.2014.02.025.CrossRefPubMed

18.

Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, Kono Y, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2017;45(1):169–77. doi:10.1111/apt.13841.CrossRefPubMed

19.

Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11(4):e1001624. doi:10.1371/journal.pmed.1001624.CrossRefPubMedPubMedCentral

20.

Cucchetti A, Trevisani F, Pecorelli A, Erroi V, Farinati F, Ciccarese F, et al. Estimation of lead-time bias and its impact on the outcome of surveillance for the early diagnosis of hepatocellular carcinoma. J Hepatol. 2014;61(2):333–41. doi:10.1016/j.jhep.2014.03.037.CrossRefPubMed

21.

Thein HH, Campitelli MA, Yeung LT, Zaheen A, Yoshida EM, Earle CC. Improved survival in patients with viral hepatitis-induced hepatocellular carcinoma undergoing recommended abdominal ultrasound surveillance in Ontario: a population-based retrospective cohort study. PLoS One. 2015;10(9):e0138907. doi:10.1371/journal.pone.0138907.CrossRefPubMedPubMedCentral

22.

Wu CY, Hsu YC, Ho HJ, Chen YJ, Lee TY, Lin JT. Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study. Gut. 2016;65(4):693–701. doi:10.1136/gutjnl-2014-308786.CrossRefPubMed

23.

Cucchetti A, Garuti F, Pinna AD, Trevisani F. Italian liver Cancer g. Length time bias in surveillance for hepatocellular carcinoma and how to avoid it. Hepatol Res. 2016;46(12):1275–80. doi:10.1111/hepr.12672.CrossRefPubMed

24.

Oeda S, Iwane S, Takasaki M, Furukawa NE, Otsuka T, Eguchi Y, et al. Optimal follow-up of patients with viral hepatitis improves the detection of early-stage hepatocellular carcinoma and the prognosis of survival. Intern Med. 2016;55(19):2749–58. doi:10.2169/internalmedicine.55.6730.CrossRefPubMedPubMedCentral

25.

Johnson P, Berhane S, Kagebayashi C, Satomura S, Teng M, Fox R, et al. Impact of disease stage and aetiology on survival in hepatocellular carcinoma: implications for surveillance. Br J Cancer. 2017;116(4):441–7. doi:10.1038/bjc.2016.422.CrossRefPubMedPubMedCentral

26.

Singal AG, Mittal S, Yerokun OA, Ahn C, Marrero J, Yopp A, et al. Hepatocellular carcinoma screening associated with early tumor detection and Improved survival among patients with cirrhosis in the United States. Am J Med. 2017; doi:10.1016/j.amjmed.2017.01.021.

27.

Marks RM, Ryan A, Heba ER, Tang A, Wolfson TJ, Gamst AC, et al. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. AJR Am J Roentgenol. 2015;204(3):527–35. doi:10.2214/AJR.14.12986.CrossRefPubMed

28.

Besa C, Lewis S, Pandharipande PV, Chhatwal J, Kamath A, Cooper N, et al. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol (NY). 2017;42(1):179–90. doi:10.1007/s00261-016-0841-5.CrossRef

29.

Jo PC, Jang HJ, Burns PN, Burak KW, Kim TK, Wilson SR. Integration of contrast-enhanced US into a multimodality approach to imaging of nodules in a cirrhotic liver: how I do it. Radiology. 2017;282(2):317–31. doi:10.1148/radiol.2016151732.CrossRefPubMed

30.

Sutherland T, Watts J, Ryan M, Galvin A, Temple F, Vuong J, et al. Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: direct comparison with ultrasound screening. J Med Imaging Radiat Oncol. 2017;61(1):34–9. doi:10.1111/1754-9485.12513.CrossRefPubMed

31.

Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006;4(1):111–7.CrossRefPubMed

32.

Lee E, Edward S, Singal AG, Lavieri MS, Volk M. Improving screening for hepatocellular carcinoma by incorporating data on levels of alpha-fetoprotein, over time. Clin Gastroenterol Hepatol. 2013;11(4):437–40. doi:10.1016/j.cgh.2012.11.029.CrossRefPubMed

33.

Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110–8. doi:10.1053/j.gastro.2009.04.005.CrossRefPubMedPubMedCentral

34.

El-Serag HB, Kanwal F, Davila JA, Kramer J, Richardson P. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis. Gastroenterology. 2014;146(5):1249–1255 e1. doi:10.1053/j.gastro.2014.01.045.CrossRefPubMedPubMedCentral

35.

•• White DL, Richardson P, Tayoub N, Davila JA, Kanwal F, El-Serag HB. The updated model: an adjusted serum alpha-fetoprotein-based algorithm for hepatocellular carcinoma detection with hepatitis C virus-related cirrhosis. Gastroenterology. 2015;149(7):1986–7. doi:10.1053/j.gastro.2015.10.004. An adjusted AFP screening algorithm incorporating longitudinal biomarker information showed excellent performance characteristics. CrossRefPubMedPubMedCentral

36.

Yapali S, Talaat N, Lok AS. Management of hepatitis B: our practice and how it relates to the guidelines. Clin Gastroenterol Hepatol. 2014;12(1):16–26. doi:10.1016/j.cgh.2013.04.036.CrossRefPubMed

37.

El-Serag HB, Kanwal F. alpha-Fetoprotein in hepatocellular carcinoma surveillance: mend it but do not end it. Clin Gastroenterol Hepatol. 2013;11(4):441–3. doi:10.1016/j.cgh.2012.12.046.CrossRefPubMed

38.

Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009;49(3):851–9. doi:10.1002/hep.22734.CrossRefPubMed

39.

Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, Temple S, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015;13(3):594–601 e1. doi:10.1016/j.cgh.2014.08.013.CrossRefPubMed

40.

Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63(3):827–38. doi:10.1002/hep.28368.CrossRefPubMed

41.

•• Heimbach J, Kulik LM, Finn R, Sirlin CB, Abecassis M, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017; doi:10.1002/hep.29086. New AASLD guidelines for screening, diagnosis and treatment of hepatocellular carcinoma.

42.

European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43. doi:10.1016/j.jhep.2011.12.001.CrossRef

43.

Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4(2):439–74. doi:10.1007/s12072-010-9165-7.CrossRefPubMedPubMedCentral

44.

Bruix J, Sherman M. American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2. doi:10.1002/hep.24199.CrossRefPubMedPubMedCentral

45.

Kokudo N, Hasegawa K, Akahane M, Igaki H, Izumi N, Ichida T, et al. Evidence-based clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2013 update (3rd JSH-HCC guidelines). Hepatol Res. 2015;45(2) doi:10.1111/hepr.12464.

46.

World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. WHO, Geneva 2015.

47.

Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47. doi:10.1111/j.1365-2036.2009.04014.x.CrossRefPubMed

48.

Tong MJ, Blatt LM, Kao VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol. 2001;16(5):553–9.CrossRefPubMed

49.

Chang TS, Wu YC, Tung SY, Wei KL, Hsieh YY, Huang HC, et al. Alpha-fetoprotein measurement benefits hepatocellular carcinoma surveillance in patients with cirrhosis. Am J Gastroenterol. 2015;110(6):836–844; quiz 45. doi:10.1038/ajg.2015.100.CrossRefPubMed

50.

Atiq O, Tiro J, Yopp AC, Muffler A, Marrero JA, Parikh ND, et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. Hepatology. 2016; doi:10.1002/hep.28895.PubMed

51.

Kim DY, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer. 2012;1(1):2–14. doi:10.1159/000339016.CrossRefPubMedPubMedCentral

52.

Kim SY, An J, Lim YS, Han S, Lee JY, Byun JH, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol. 2016; doi:10.1001/jamaoncol.2016.3147.

53.

Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, et al. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol. 2016;22(1):262–74. doi:10.3748/wjg.v22.i1.262.CrossRefPubMedPubMedCentral

54.

Di Bisceglie AM, Hoofnagle JH. Elevations in serum alpha-fetoprotein levels in patients with chronic hepatitis B. Cancer. 1989;64(10):2117–20.CrossRefPubMed

55.

Di Bisceglie AM, Sterling RK, Chung RT, Everhart JE, Dienstag JL, Bonkovsky HL, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol. 2005;43(3):434–41.CrossRefPubMed

56.

Zhou XD, Tang ZY, Fan J, Zhou J, Wu ZQ, Qin LX, et al. Intrahepatic cholangiocarcinoma: report of 272 patients compared with 5,829 patients with hepatocellular carcinoma. J Cancer Res Clin Oncol. 2009;135(8):1073–80. doi:10.1007/s00432-009-0547-y.CrossRefPubMed

57.

•• Tayob N, Lok AS, Do KA, Feng Z. Improved detection of hepatocellular carcinoma by using a longitudinal alpha-fetoprotein screening algorithm. Clin Gastroenterol Hepatol. 2016;14(3):469–75. doi:10.1016/j.cgh.2015.07.049. e2. New parametric empirical Bayesian (PEB) screening algorithm incorporating longitudinal biomarker information into surveillance. CrossRefPubMed

58.

McIntosh MW, Urban N. A parametric empirical Bayes method for cancer screening using longitudinal observations of a biomarker. Biostatistics. 2003;4(1):27–40. doi:10.1093/biostatistics/4.1.27.CrossRefPubMed

59.

Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138(2):493–502. doi:10.1053/j.gastro.2009.10.031.CrossRefPubMed

60.

Gounder PP, Bulkow LR, Meltzer MI, Bruce MG, Hennessy TW, Snowball M, et al. Cost-effectiveness analysis of hepatocellular carcinoma screening by combinations of ultrasound and alpha-fetoprotein among Alaska Native people, 1983-2012. Int J Circumpolar Health. 2016;75:31115. doi:10.3402/ijch.v75.31115.CrossRef

61.

Kudo M. Alpha-fetoprotein-L3: useful or useless for hepatocellular carcinoma? Liver Cancer. 2013;2(3–4):151–2. doi:10.1159/000343847.PubMedPubMedCentral

62.

Yi X, Yu S, Bao Y. Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis. Clin Chim Acta. 2013;425:212–20. doi:10.1016/j.cca.2013.08.005.CrossRefPubMed

63.

Chaiteerakij R, Zhang X, Addissie BD, Mohamed EA, Harmsen WS, Theobald PJ, et al. Combinations of biomarkers and Milan criteria for predicting hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl. 2015;21(5):599–606. doi:10.1002/lt.24117.CrossRefPubMedPubMedCentral

64.

Hayashi K, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, et al. Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol. 1999;94(10):3028–33. doi:10.1111/j.1572-0241.1999.01378.x.PubMed

65.

Kumada T, Nakano S, Takeda I, Kiriyama S, Sone Y, Hayashi K, et al. Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. J Hepatol. 1999;30(1):125–30.CrossRefPubMed

66.

Leerapun A, Suravarapu SV, Bida JP, Clark RJ, Sanders EL, Mettler TA, et al. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol. 2007;5(3):394–402; quiz 267. doi:10.1016/j.cgh.2006.12.005.CrossRefPubMedPubMedCentral

67.

Wallin R, Prydz H. Studies on a subcellular system for vitamin K-dependent carboxylation. Thromb Haemost. 1979;41(3):529–36.PubMed

68.

Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med. 1984;310(22):1427–31. doi:10.1056/NEJM198405313102204.CrossRefPubMed

69.

Tsai SL, Huang GT, Yang PM, Sheu JC, Sung JL, Chen DS. Plasma des-gamma-carboxyprothrombin in the early stage of hepatocellular carcinoma. Hepatology. 1990;11(3):481–8.CrossRefPubMed

70.

Cui R, Wang B, Ding H, Shen H, Li Y, Chen X. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma. Chin Med J. 2002;115(1):42–5.PubMed

71.

Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, Omata M. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int. 2008;2(1):17–30. doi:10.1007/s12072-007-9038-x.CrossRefPubMed

72.

Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer. 1998;82(9):1643–8.CrossRefPubMed

73.

Ikoma J, Kaito M, Ishihara T, Nakagawa N, Kamei A, Fujita N, et al. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum des-gamma-carboxy prothrombin: a prospective study. Hepato-Gastroenterology. 2002;49(43):235–8.PubMed

74.

Makuuchi M, Kokudo N, Arii S, Futagawa S, Kaneko S, Kawasaki S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res. 2008;38(1):37–51. doi:10.1111/j.1872-034X.2007.00216.x.CrossRefPubMed

75.

Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology. 2003;37(5):1114–21. doi:10.1053/jhep.2003.50195.CrossRefPubMed

76.

Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark. 2007;3(2):79–87.CrossRefPubMed

77.

Ertle JM, Heider D, Wichert M, Keller B, Kueper R, Hilgard P, et al. A combination of alpha-fetoprotein and des-gamma-carboxy prothrombin is superior in detection of hepatocellular carcinoma. Digestion. 2013;87(2):121–31. doi:10.1159/000346080.CrossRefPubMed

78.

•• Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomark Prev. 2014;23(1):144–53. doi:10.1158/1055-9965.EPI-13-0870. Original description of the GALAD scoring system incorporating patient demographic information and biomarkers for surveillance. CrossRef

79.

Best J, Bilgi H, Heider D, Schotten C, Manka P, Bedreli S, et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. Z Gastroenterol. 2016;54(12):1296–305. doi:10.1055/s-0042-119529.CrossRefPubMed

80.

Berhane S, Toyoda H, Tada T, Kumada T, Kagebayashi C, Satomura S, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol. 2016;14(6):875–886 e6. doi:10.1016/j.cgh.2015.12.042.CrossRefPubMed

81.

Duarte-Salles T, Misra S, Stepien M, Plymoth A, Muller D, Overvad K, et al. Circulating osteopontin and prediction of hepatocellular carcinoma development in a large European population. Cancer Prev Res (Phila). 2016;9(9):758–65. doi:10.1158/1940-6207.CAPR-15-0434.CrossRef

82.

Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology. 2012;55(2):483–90. doi:10.1002/hep.24703.CrossRefPubMed

83.

da Costa AN, Plymoth A, Santos-Silva D, Ortiz-Cuaran S, Camey S, Guilloreau P, et al. Osteopontin and latent-TGF beta binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. Int J Cancer. 2015;136(1):172–81. doi:10.1002/ijc.28953.CrossRefPubMed

84.

Cao B, Yang L, Rong W, Feng L, Han N, Zhang K, et al. Latent transforming growth factor-beta binding protein-1 in circulating plasma as a novel biomarker for early detection of hepatocellular carcinoma. Int J Clin Exp Pathol. 2015;8(12):16046–54.PubMedPubMedCentral

85.

Shen Q, Fan J, Yang XR, Tan Y, Zhao W, Xu Y, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol. 2012;13(8):817–26. doi:10.1016/S1470-2045(12)70233-4.CrossRefPubMed

86.

Zhu WW, Guo JJ, Guo L, Jia HL, Zhu M, Zhang JB, et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res. 2013;19(14):3944–54. doi:10.1158/1078-0432.CCR-12-3363.CrossRefPubMed

87.

Vongsuvanh R, van der Poorten D, Iseli T, Strasser SI, McCaughan GW, George J. Midkine increases diagnostic yield in AFP negative and NASH-related hepatocellular carcinoma. PLoS One. 2016;11(5):e0155800. doi:10.1371/journal.pone.0155800.CrossRefPubMedPubMedCentral

88.

Yang J, Li J, Dai W, Wang F, Shen M, Chen K, et al. Golgi protein 73 as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis. Exp Ther Med. 2015;9(4):1413–20. doi:10.3892/etm.2015.2231.PubMedPubMedCentral

89.

Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005;43(6):1007–12. doi:10.1016/j.jhep.2005.05.028.CrossRefPubMed

90.

Jia X, Liu J, Gao Y, Huang Y, Du Z. Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis. Arch Med Res. 2014;45(7):580–8. doi:10.1016/j.arcmed.2014.11.002.CrossRefPubMed

91.

Lin XJ, Chong Y, Guo ZW, Xie C, Yang XJ, Zhang Q, et al. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol. 2015;16(7):804–15. doi:10.1016/S1470-2045(15)00048-0.CrossRefPubMed

92.

Huang JT, Liu SM, Ma H, Yang Y, Zhang X, Sun H, et al. Systematic review and meta-analysis: circulating miRNAs for diagnosis of hepatocellular carcinoma. J Cell Physiol. 2016;231(2):328–35. doi:10.1002/jcp.25135.CrossRefPubMed

93.

GALAD Score Calculator. 2017. http://www.mayoclinic.org/medical-professionals/model-end-stage-liver-disease/galad. Accessed March 23 2017.

94.

Addissie BD, Yang JD, Ward M, Algeciras-Schiminich A, Theobald JP, Roberts L. 647 validation of the GALAD score for Prediction of hepatocellular carcinoma at a US tertiary referral center and comparison of its performance to liver ultrasound. Gastroenterology. 2016;150(4):S1041.CrossRef

Titel: Should AFP (or Any Biomarkers) Be Used for HCC Surveillance?
verfasst von: Hager F. Ahmed Mohammed
Lewis R. Roberts
Publikationsdatum: 28.04.2017
Verlag: Springer US
Erschienen in: Current Hepatology Reports / Ausgabe 2/2017
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-017-0349-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2017

Portal Vein Thrombosis and Cirrhosis: The Role of Anticoagulation

Autoimmune Hepatitis: When Is It Safe to Stop Therapy, or Withhold Therapy Altogether?

Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much?

Are Dominant Strictures in Primary Sclerosing Cholangitis a Risk Factor for Cholangiocarcinoma?

Clinical Implications and Management of Chronic OccultHepatitis B Virus Infection